CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) working to bring respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain considerable global competitive advantage in radiopharmaceuticals.
Join us for this event where we will learn how the CARI program is exploring opportunities arising from academic discoveries and early enterprises, establishing rigorous drug development programs around selected opportunities, and driving the generation of proof-of-principle for the commercialization of new radiopharmaceutical assets.
The event will be taking place on June 23 @ 11 a.m. EST. Please register at the link below.
Dr. Bruno Paquin
Dr. Ghadeer Shubassi
Senior Business Development Manager
Dr. Stuart Cain
Associate Director, Scientific Evaluation
Dr. Lana Janes
Associate Scientist, Biologics
EVP, Bruce Power
Chair, Canadian Nuclear Isotope Council
Director Strategic Initiatives
Canadian Nuclear Isotopes Council
HAMILTON, ON, July 13, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, announced today that it has appointed four new Members to join its Board of Directors effective June 17, 2021. The new Members are as follows: Dr. Bettina Hamelin, is the current President and
Over the past few months, adMare BioInnovations and the Centre for Probe Development and Commercialization (CPDC) have shared with you information about the role and the potential of radiopharmaceuticals in healthcare and in the life sciences ecosystem in Canada. Now we want to share some further thoughts from our resident experts bringing this initiative and this potential to
Hamilton, Ontario (March 10, 2021) – The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Bruno Paquin as Chief Executive Officer (CEO). The CEO appointment has taken effect on March 4, 2021. Dr. John Thornback, Chair of the Board of Directors said, “We are pleased to announce that